Speedy NICE Support For Eisai's Lenvima In Liver Cancer
Executive Summary
It took NICE nearly three years to offer routine access to Lenvima for thyroid cancer but it has taken just three months from European approval to recommend the drug for advanced or unresectable hepatocellular carcinoma.